Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL7062339 | 0.87 | RNPEP (0.39) | FPR2TP53ALDH1A1MEN1KMT2A | |
| Toluene SCHEMBL7062281 | 0.86 | KDM4E (0.40) | TP53ALDH1A1MMEMEN1NPC1 | |
| Fluorobenzene SCHEMBL7062894 | 0.85 | TP53 (0.39) | TP53ALDH1A1MEN1NPC1KMT2A | |
| Chlorobenzene SCHEMBL7062313 | 0.85 | MAPK1 (0.39) | TP53ALDH1A1LMNA | |
| 1,2-Dichlorobenzene SCHEMBL7065989 | 0.85 | TP53 (0.39) | TP53ALDH1A1NPC1RAB9ALMNA | |
| Isopropylbenzene SCHEMBL7066885 | 0.85 | ALDH1A1 (0.39) | TP53ALDH1A1MMP9MMEMEN1 | |
| Ethylbenzene SCHEMBL7062310 | 0.84 | TP53 (0.41) | TP53ALDH1A1MME | |
| SCHEMBL8998207 | 0.83 | RNPEP (0.41) | TP53ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL29887276 | 0.83 | RNPEP (0.41) | TP53ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL27558964 | 0.83 | RNPEP (0.41) | TP53ALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | THOMPSON LORIN A (US) | 2003-07-10 | — | — | US | claimed |
| US-6503901-B1 | Alzheimer*s disease and Down*s syndrome treatment | BRISTOL MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | claimed |
| EP-1218377-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-07-03 | — | — | EP | claimed |
| WO-2001027108-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | THOMPSON LORIN A (US) | 2003-07-10 | — | — | US | disclosed |
| US-6503901-B1 | Alzheimer*s disease and Down*s syndrome treatment | BRISTOL MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| EP-1222176-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-1218377-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001027108-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001027091-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | APP, APH1A, BACE1 | FPR2 1875/4885TP53 3847/4885ALDH1A1 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.